Literature DB >> 35144823

Leiomyoma with nuclear atypia: Rare diseases that present a common diagnostic problem.

Jian-Jun Wei1.   

Abstract

Leiomyoma with nuclear atypia describes a group of uterine smooth muscle tumors with a wide range of histologic and clinical presentations and remarkable nuclear atypia. These include fumarate hydratase-deficient leiomyoma (FH-LM), intravenous leiomyomatosis (IV-LM), and leiomyoma with bizarre nuclei (LM-BN). Other uterine mesenchymal tumors, such as perivascular epithelioid tumor (PEComa) and inflammatory myofibroblastic tumors (IMFT) are the mimickers of leiomyoma with nuclear atypia. LM-BN is the primary tumor model with a long history in gynecologic pathology, but the histogenesis of LM-BN remains largely unknown. Differentiating LM-BN from other benign variants, tumors with uncertain malignant potential (STUMP), or fully malignant leiomyosarcoma (LMS) can be diagnostically challenging. Recent progress has improved the diagnosis of many types of leiomyoma with nuclear atypia based on their specific histology and molecular alterations. LM-BN is now a diagnosis of exclusion. In this article, I review the history of leiomyoma with nuclear atypia and compare the clinical, histologic, and molecular features of LM-BN with those of its mimics. In particular, I highlight the current progress made in molecular genetics and pitfalls in the diagnosis of different myogenic tumors with nuclear atypia.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  Fumarate hydratase-deficient leiomyoma; Gene mutation; IMFT, Leiomyosarcoma, STUMP; Intravenous leiomyomatosis; Leiomyoma with bizarre nuclei; Leiomyosarcoma; Nuclear atypia; PEComa

Mesh:

Substances:

Year:  2022        PMID: 35144823      PMCID: PMC9035108          DOI: 10.1053/j.semdp.2022.01.006

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.893


  53 in total

1.  Leiomyosarcoma of the uterus.

Authors:  W M Christopherson; E O Williamson; L A Gray
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

2.  Surgical pathology of the uterine corpus.

Authors:  M R Hendrickson; R L Kempson
Journal:  Major Probl Pathol       Date:  1979

Review 3.  Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.

Authors:  Philip P C Ip; Annie N Y Cheung
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2011-08-23       Impact factor: 5.237

4.  Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.

Authors:  Vera M Abeler; Odd Røyne; Steinar Thoresen; Håvard E Danielsen; Jahn M Nesland; Gunnar B Kristensen
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

5.  Inflammatory pseudotumor of the uterus.

Authors:  C B Gilks; G P Taylor; P B Clement
Journal:  Int J Gynecol Pathol       Date:  1987       Impact factor: 2.762

6.  Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.

Authors:  S Leibsohn; G d'Ablaing; D R Mishell; J B Schlaerth
Journal:  Am J Obstet Gynecol       Date:  1990-04       Impact factor: 8.661

7.  Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases.

Authors:  Amy Ly; Anne M Mills; Jesse K McKenney; Bonnie L Balzer; Richard L Kempson; Michael R Hendrickson; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

8.  Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients.

Authors:  Nancy M Joseph; David A Solomon; Norma Frizzell; Joseph T Rabban; Charles Zaloudek; Karuna Garg
Journal:  Am J Surg Pathol       Date:  2015-11       Impact factor: 6.394

9.  Intravenous leiomyomatosis of the uterus. A clinicopathological analysis of 16 cases with unusual histologic features.

Authors:  P B Clement; R H Young; R E Scully
Journal:  Am J Surg Pathol       Date:  1988-12       Impact factor: 6.394

10.  Integrative genomic and transcriptomic analysis of leiomyosarcoma.

Authors:  Priya Chudasama; Sadaf S Mughal; Mathijs A Sanders; Daniel Hübschmann; Inn Chung; Katharina I Deeg; Siao-Han Wong; Sophie Rabe; Mario Hlevnjak; Marc Zapatka; Aurélie Ernst; Kortine Kleinheinz; Matthias Schlesner; Lina Sieverling; Barbara Klink; Evelin Schröck; Remco M Hoogenboezem; Bernd Kasper; Christoph E Heilig; Gerlinde Egerer; Stephan Wolf; Christof von Kalle; Roland Eils; Albrecht Stenzinger; Wilko Weichert; Hanno Glimm; Stefan Gröschel; Hans-Georg Kopp; Georg Omlor; Burkhard Lehner; Sebastian Bauer; Simon Schimmack; Alexis Ulrich; Gunhild Mechtersheimer; Karsten Rippe; Benedikt Brors; Barbara Hutter; Marcus Renner; Peter Hohenberger; Claudia Scholl; Stefan Fröhling
Journal:  Nat Commun       Date:  2018-01-10       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.